Evaluation of photodynamic treatment efficiency on glioblastoma cells received from malignant lesions: initial studies
| Autor: | Dobroslav Kyurkchiev, Ivan Angelov, Tsanislava Genova-Hristova, Krassimir Minkin, Oxana Semyachkina-Glushkovskaya, Ekaterina Borisova, Kalina Tumangelova-Yuzeir |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Protoporphyrin IX
business.industry medicine.medical_treatment Cell Becton dickinson Photodynamic therapy medicine.disease photodynamic therapy (PDT) Cancer treatment Glioblastoma multiform (GBM) chemistry.chemical_compound medicine.anatomical_structure chemistry in vitro cell studies medicine Cancer research Photosensitizer delta-aminolevulinic acid/ protoporphyrin IX (5-ALA/PpIX) business Glioblastoma |
| Zdroj: | Saratov Fall Meeting 2017: Optical Technologies in Biophysics and Medicine XIX. |
| DOI: | 10.1117/12.2314443 |
| Popis: | Photodynamic therapy is well-established and extensively used method in treatment of different cancer types. This research reveals its potential in the treatment of cultivated human glioblastoma cells with adherent morphology. As the blood-brain barrier (BBB) permeability of the drugs is a significant problem that could not be solved easily for large biomolecules, we search for an appropriate low-molecular weight photosensitizer that could be applied for photodynamic treatment of glioblastoma cells. We used delta-aminolevulinic acid (5-ALA), which could pass BBB and plays the role of precursor of a protoporphyrin IX (PpIX) – photosensitizer, that is accumulated selectively in the tumour cells and could be a proper tool in PDT of glioblastoma. However, differences from patient to patient and between the cell activities could also lead to different effectiveness of the PDT treatment of the tumour areas. Therefore in our study we investigated not only the effect of using different fluence rates and light doses, but aims to establish more efficient values for further clinical applications for each sub-type of the GBM lesions. For the needs of PDT application an illumination device was developed in Laboratory of Biophotonics, BAS based on light-emitting diode (LED) matrix light sources for therapeutic application emitting at 635 nm. The device is optimized for PDT in combination with aminolevulinic acid/protoporphyrin IX applied as a photosensitizer drug. By the means of FACSCalibur flow cytometer (Becton Dickinson, USA) and Cell Quest Software was made evaluation of PDT effect on used human glioblastoma cells. Treatment of glioblastoma tumours continues to be a very serious issue and there is growing need in development of new concepts, methods and cancer-fighting strategies. PDT may contribute in accomplishing better results in cancer treatment and can be applied as well in combination with other techniques. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|